Health Care • Biotechnology: Pharmaceutical Preparations
$29.99 ▼ -0.88
(-2.85%)
MKT CAP: $2.24B • VOL: 1.36M
52W L $11 52W H $34
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$25
MEDIAN
$34
MEAN
$34
HIGH
$41
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SDGR TAPE
SDGR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $36.29 | $34.49 | 2025-02-14 | $27.29 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $37.79 | $35.39 | 2025-02-06 | $28.19 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $34.19 | $32.99 | 2025-01-29 | $28.79 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $30.59 | — | 2025-01-17 | $29.39 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $26.39 | $28.49 | 2025-01-09 | $26.69 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $35.69 | $31.19 | 2024-12-18 | $26.09 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $29.09 | $30.29 | 2024-12-04 | $27.89 | -4.3% | 48% | C |